cvs caremark glp-1 coverage recently announced that Wegovy will become the preferred medication for obesity treatment starting in July, leaving many questions for those currently prescribed Zepbound and other obesity medications. OAC is 🚨 CVS Caremark Finally Added

Thanks for reading and subscribing to Ground Truths

J Clin Endocrinol Metab 98:25532561

During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 1.9% and 1.2% of patients randomized to RYBELSUS 14 mg and empagliflozin 25 mg, respectively

Brain and nervous system: Inflammatory signaling can influence fatigue, mood, sleep, and pain sensitivity, but these symptoms are not specific to metabolic inflammation and have complex drivers

doi: 10.1111/dom.13420

Research shows GLP-1 receptor agonists effectively reduce visceral fat, though whether this reduction is preferential compared to subcutaneous fat continues to be investigated